Cite
Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
MLA
Leone, Francesco, et al. “Panitumumab in Combination with Gemcitabine and Oxaliplatin Does Not Prolong Survival in Wild-Type KRAS Advanced Biliary Tract Cancer: A Randomized Phase 2 Trial (Vecti-BIL Study).” Cancer (0008543X), vol. 122, no. 4, Feb. 2016, pp. 574–81. EBSCOhost, https://doi.org/10.1002/cncr.29778.
APA
Leone, F., Marino, D., Cereda, S., Filippi, R., Belli, C., Spadi, R., Nasti, G., Montano, M., Amatu, A., Aprile, G., Cagnazzo, C., Fasola, G., Siena, S., Ciuffreda, L., Reni, M., & Aglietta, M. (2016). Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study). Cancer (0008543X), 122(4), 574–581. https://doi.org/10.1002/cncr.29778
Chicago
Leone, Francesco, Donatella Marino, Stefano Cereda, Roberto Filippi, Carmen Belli, Rosella Spadi, Guglielmo Nasti, et al. 2016. “Panitumumab in Combination with Gemcitabine and Oxaliplatin Does Not Prolong Survival in Wild-Type KRAS Advanced Biliary Tract Cancer: A Randomized Phase 2 Trial (Vecti-BIL Study).” Cancer (0008543X) 122 (4): 574–81. doi:10.1002/cncr.29778.